Translate AMICOR contents if you like

Monday, June 24, 2019

AD and BP

Blood Pressure Reduction and Alzheimer's Disease

-Study examines nilvadipine and cerebral blood flow, showing increased, safe flow to hippocampus

CME Author: Vicki Brower
Study Authors: Daan L. K. de Jong, Rianne A. A. de Heus, et al.
Target Audience and Goal Statement:
Neurologists, geriatricians, cardiologists, internists, family medicine specialists
The goal of this study was to determine whether blood pressure reduction with antihypertensive medication could affect cerebral blood flow, in particular, to the hippocampus and posterior cingulate cortex, in patients with Alzheimer clinical syndrome in a mild-to-moderate stage of dementia.
Questions Addressed:
  • Can the calcium channel blocker nilvadipine increase cerebral blood flow (CBF) in patients with mild-to-moderate Alzheimer's disease (AD)?
  • What parts of the brain are affected by lowering of blood pressure?
  • What effect does this have on cerebral autoregulation?

Action Points

No comments: